EC OKs label extension for BMS's Orencia
This article was originally published in Scrip
The European Commission has approved an expanded indication for Bristol-Myers Squibb's Orencia (abatacept) for use in combination with methotrexate for moderate-to-severe active rheumatoid arthritis (RA) in patients who have responded inadequately to previous therapy with one or more disease-modifying antirheumatic drugs (DMARDs) including methotrexate or a TNF-alpha inhibitor.
You may also be interested in...
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.